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Nienke Vet and colleagues have evaluated the influence of daily sedation interruptions 
(DSI) in PICU. This was ambitious:  bias is hard to avoid and recruitment rates in such 
studies are poor, which ultimately restrict the strength of conclusions. Nevertheless, 
their results suggest that if behavioral tools already drive sedation delivery, then DSI 
will not substantially influence the duration of ventilation. These findings are consistent 
with recent reports from adult intensive care (1).  
 
A pause in drug delivery allows plasma concentration to fall followed by reduction in 
effect site concentration and subsequent arousal. However, the lag time can be 
significant (Figure 1a). Recovery may be further delayed by the presence and influence 
of midazolam’s alpha-hydroxy metabolite that has half the activity of the parent drug 
(2).  Other drugs used for sedation also have influence; a three-drug combination (e.g., 
midazolam, propofol, and alfentanil) can triple the duration of effect compared with 
propofol alone (3). In the current study additional sedative and analgesic drugs were 
used “as required”. This may have contributed to the lack of impact from midazolam 
interruption. Variation in recovery from sedation is complicated by the high prevalence 
of renal failure, hepatic failure, and concomitant administration of CYP3A inhibitors in 
PICU patients. Sedation requirements vary widely not only with age, diagnosis and 
clinical state, but also between similar patients.  
 
Sedation has parallels with innovations in postoperative pain control in children: 
intermittent drug use was replaced by continuous infusions, then patient and nurse 
controlled analgesia (PCA/NCA) with pain score monitoring. Further optimization 
combined low dose continuous infusions modulated by PCA/NCA. PICU sedation is in 
need of similar improvement but can this impact on patient outcomes? Practitioners of 
anaesthesia are also aware of emergence delirium complicating recovery. Could a 
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similar phenomenon complicate midazolam interruption, necessitating reintroduction 
of the drug prematurely?  
 
The value of DSI (4,5,6) remains unclear. The results of this current study could simply 
reflect the strong history in the Netherlands of good sedation practice including a 
relative sparing use of sedatives.  This is supported by the relatively low dose of 
midazolam used compared to a previous paediatric study (6). One conclusion is that 
recovery from sedation relates to the overall cumulative “sedation burden” and that 
minimizing the exposure with effective behavioral scoring linked to delivery, optimizes 
recovery irrespective of DSI and other factors. 
 
Interventions such as those described by Vet and colleagues are complex. They consist 
of multiple linked elements: (7) context and setting (workload, resources, staffing); ICU 
staff characteristics (skill mix, training,) and clinical processes (complexity of proocols, 
algorithms, decision-making and perceived risk) (8).  Understanding these components 
is critical to interpreting and generalizing study findings (9). This study does not 
provide contextual information that may help explain the results. An indication of the 
degree of compliance and nursing perspectives about the DSI may assist with 
interpreting the findings.  Qualitative studies exploring non-adherence to DSI have 
highlighted a lack of nursing acceptance due to patient agitation and the subsequent risk 
of adverse events associated with more wakeful patients (11, 12). The UK Medical 
Research Council recommends that a process evaluation should accompany trials of 
complex interventions. (9). 
 
Can tolerance be manipulated by modifying practice?  Techniques that should be 
considered include: avoiding drugs particularly associated with tolerance such as 
midazolam, moderating early exposure to high doses of analgesics and sedatives to 
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prevent acute tolerance, drug-sparing strategies such as drug cycling or polypharmacy 
mixtures, and returning to low dose propofol, a drug that has been legislated out of PICU 
in many countries. Midazolam remains the most popular sedative despite association 
with withdrawal phenomena of up to 35%  (13). The frequency and severity of tolerance 
and withdrawal is related to the cumulative “drug burden” and higher doses (>300 
mcg/kg/h) (14). A sedated patient is thought to be easier to nurse (15) and even in this 
current study children were sedated with mean midazolam doses (183-240 mcg/kg/h) 
to the deeper end of the sedation scale. There are alternatives to midazolam. Alpha-2 
agonists can provide effective sedation either as a straight midazolam replacement or as 
a supporting drug  (16,17). Currently there are no substantial data to determine if other 
drug combinations can reduce tolerance and accelerate recovery. 
 
Acute exposure to high doses of high-efficacy short-acting opioids (e.g. fentanyl, 
remifentanil) is linked to accelerated drug tolerance (18) and delay in recovery. Fast 
track paediatric cardiac surgery has moved away from high doses fentanyl 100 mcg/kg 
or more to 10-15 mcg/kg over the perioperative period resulting in earlier extubation 
and accelerated recovery.  There are potentially transferable lessons from this 
experience that could reduce tolerance in PICU patients. Drug delivery must  reflect the 
age and context dependent pharmacokinetics. For example while drug delivery in the 
young infant needs to be high during the loading phase, downward adjustment is 
necessary during maintenance, reflecting reduced elimination compared to the older 
infant (Figure 1b).  Unfortunately, behavioral scoring may be impossible in this early 
phase if neuromuscular blocking drugs are used, and higher doses than necessary may 
be continued.  Rotating drug sedation and analgesic regimens, or using non-
pharmacological strategies to maintain comfort have been used to try to limit drug 
requirements. While this approach makes sense there are no data to support it.  
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The SLEEPs trial (16) demonstrated that neither morphine/midazolam nor 
morphine/clonidine alone could always provide complete sedation.  A third agent was 
often required. The choice of the third agent may be important: in the current study 
multiple rescue drugs were used. While propofol as a major sedative agent has been 
eliminated from use in PICU due to fears of propofol infusion syndrome, it continues to 
be used cautiously by some, even in countries where the drug is officially discouraged.  
Low-dose infusion (0-4 mg/kg/h) with careful surveillance for accumulation and lactic 
acidosis deserves to be reconsidered as a third-line drug.   
 
Sedation is often treated as a necessary evil in PICU: the primary disease and its 
treatment is naturally the main focus while sedation is managed generically. During 
recovery the secondary problems associated with sedation (e.g., nosocomial infection, 
poor gut motility and behavioral change) become lost within the disease and general 
PICU experience. Under-sedation and over-sedation are both harmful: minimizing 
sedation exposure and their adverse effects are important.  Optimized matching of 
delivery to sedation requirement provides another marginal gain in the critically ill child 
that can contribute to improving patient outcomes. 
On behalf of all authors, the corresponding author states that there is no conflict of 
interest. 
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Figure 1a. Plasma concentrations and effect in a 2-year-old child given protocol midazolam 
bolus (0.1 mg/kg) and infusion changes (100 mcg/kg/h step changes) every 30 min to achieve 
sedation. Infusion was stopped at 180 min. Sedation recovery lags behind the decline in 
plasma concentration. Amplitudes in the 11.5-30 Hz (beta) frequency band were used as an 
EEG effect measure. Pharmacodynamic parameter estimates were from Mandema J et al. 
Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of 
midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteer. Clin 
Pharm Ther 1992;51:715-28 
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Figure 1b. Plasma concentrations and effect in a neonate given protocol midazolam bolus 
(0.1 mg/kg) on two early occasions (5 min interval) to achieve sedation. Plasma concentration 
declines slowly because of slow clearance. Sedation recovery lags way behind the decline in 
plasma concentration even though a maintenance infusion was not even given.  
Pharmacodynamic parameter estimates were from Mandema J et al. Pharmacokinetic-
pharmacodynamic modeling of the central nervous system effects of midazolam and its main 
metabolite alpha-hydroxymidazolam in healthy volunteer. Clin Pharm Ther 1992;51:715-28 
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